


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

HAMMERMAN, *et al.*
Serial No.: 09/472,662
Filed: December 27, 1999
For: COMPOSITION AND METHOD
FOR IMPROVING FUNCTION
OF EMBRYONIC KIDNEY
TRANSPLANTS

) Examiner: F. MOEZIE

) Art Unit: 1653

)
CERTIFICATE OF MAILING
COPY
I hereby certify that this correspondence, including listed
enclosures, is being deposited with the United States Postal
Service as First Class Mail in an envelope addressed to:
Assistant Commissioner for Patents, Washington, D.C. 20231
on October 4, 2001.
)
Signed: 
Mary McFarland

RESPONSE TO OFFICE ACTION

Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

This amendment is in response to the Office Action mailed June 5, 2001. A Petition for Extension of Time for one month, together with the required fee pursuant to 37 C.F.R. 1.17(a)(1), extending the period for response to October 5, 2001, are submitted herewith making this a timely response.

The Commissioner is authorized to charge any additional fees, including any extension fees, which may be required, or credit any overpayment to Deposit Account No. 06-1300 (Our Order No. A-68752-1/RFT/RMS).

AMENDMENTS

In the Claims:

Please amend the claims as follows:

3. (Amended) Embryonic metanephric tissue which has been pretreated with a growth factor composition comprising at least one growth factor for metanephric development wherein said pretreated metanephric tissue has enhanced renal development or function upon transplantation into recipients as compared to similarly transplanted metanephric tissue which has not been pretreated with said growth factor composition.
4. (Amended) The embryonic metanephric tissue of claim 3 wherein said growth factor is selected from the group consisting of insulin-like growth factor I, insulin-like growth factor II, vascular endothelial growth factor, transforming growth factor alpha, transforming growth factor beta, hepatocyte growth factor,

Serial No.: 09/472,662
Filing Date: December 27, 1999

fibroblast growth factors, platelet-derived growth factor, leukemia inhibitory factor, angiopoetins 1 and 2, bone morphogenetic proteins, nerve growth factor, and growth hormone.

6. (Amended) The method of claim 5 wherein said growth factor is selected from the group consisting of insulin-like growth factor I, insulin-like growth factor II, vascular endothelial growth factor, transforming growth factor alpha, transforming growth factor beta, hepatocyte growth factor, fibroblast growth factors, platelet-derived growth factor, leukemia inhibitory factor, angiopoetins 1 and 2, bone morphogenetic proteins, nerve growth factor, and growth hormone.

11. (Amended) A growth factor composition for enhancing the growth and development of embryonic metanephric tissue comprising two or more growth factors for metanephric development.

12. (Amended) The growth factor composition of claim 11 wherein said two or more growth factors are selected from the group consisting of insulin-like growth factor I, insulin-like growth factor II, vascular endothelial growth factor, transforming growth factor alpha, transforming growth factor beta, hepatocyte growth factor, fibroblast growth factors, platelet-derived growth factor, leukemia inhibitory factor, angiopoetins 1 and 2, bone morphogenetic proteins, nerve growth factor, and growth hormone.

Please add the following new claims:

13. (New) The embryonic metanephric tissue of claim 3 wherein said growth factor composition comprises vitamin A.

14. (New) The method of claim 5 wherein said growth factor composition comprises vitamin A.

15. (New) The growth factor composition of claim 11 wherein said growth factor composition comprises vitamin A.

REMARKS

Claims 3-15 are pending. An Appendix of Pending Claims is attached for the Examiner's convenience.